Lir Life Sciences Corp. (CVE:SKNY) | WebDisclosure

Basculer en Français

10966	Companies
240147	Keywords
168916	Articles
129236	Press releases

Headlines Articles Press releases Lir Life Sciences Corp.

Home
Companies
Lir Life Sciences Corp.

PRESS RELEASE

published on 01/30/2026 at 00:00, 7 months 13 days ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
LIR Life Sciences Corp. announces positive interim results from a mouse study on CPP-enabled, needle-free delivery of GLP/GIP therapies, demonstrating glucose control potential

Interim Results Lir Life Sciences Corp. GLP/GIP Therapies CPP-enabled Delivery Skin-applied Formulation
BRIEF

published on 01/23/2026 at 00:05, 7 months 20 days ago

LIR Life Sciences finalise le protocole d'étude pour l'évaluation des agents transdermiques

Administration Transdermique LIR Sciences De La Vie Macromolécules Thérapeutiques Modèle De Peau De Porc Thérapies Sans Aiguilles
BRIEF

published on 01/23/2026 at 00:05, 7 months 20 days ago

LIR Life Sciences Finalizes Study Design for Evaluating Transdermal Agents

Transdermal Delivery LIR Life Sciences Therapeutic Macromolecules Porcine Skin Model Needle-free Therapies
PRESS RELEASE

published on 01/23/2026 at 00:00, 7 months 20 days ago

LIR Life Sciences Completes Design of Ex Vivo Animal Study to Evaluate Novel Transdermal Agents for Transport of Larger Therapeutic Molecules
LIR Life Sciences Corp. announces study design for transdermal penetration of therapeutic macromolecules using ex vivo porcine skin. Focus on needle-free delivery strategies for larger therapeutics

Needle-free Delivery LIR Life Sciences Therapeutic Macromolecules Transdermal Penetration Ex Vivo Porcine Skin
BRIEF

published on 01/16/2026 at 00:05, 7 months 27 days ago

LIR Life Sciences lance une étude animale sur les thérapies transdermiques contre l'obésité

Administration Transdermique Thérapie De L'obésité Étude Animale LIR Sciences De La Vie Basé Sur Les BPL/BPI
BRIEF

published on 01/16/2026 at 00:05, 7 months 27 days ago

LIR Life Sciences Initiates Animal Study on Transdermal Obesity Therapies

Transdermal Delivery Obesity Therapy Animal Study LIR Life Sciences GLP/GIP-based
PRESS RELEASE

published on 01/16/2026 at 00:00, 7 months 27 days ago

LIR Life Sciences Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation GLP/GIP-based Obesity Therapies
LIR Life Sciences Corp. announces a controlled comparative animal study to evaluate needle-free transdermal delivery of GLP/GIP-based obesity therapies. Study aims to advance transdermal platform and simplify treatment for obesity

Lir Life Sciences Corp. Obesity Therapies GLP/GIP-based Controlled Study Needle-free Transdermal Delivery
BRIEF

published on 01/09/2026 at 00:05, 8 months 3 days ago

LIR Life Sciences collabore avec Neuland Labs au développement de peptides

LIR Sciences De La Vie Laboratoires Neuland Peptides Pénétrant Dans Les Cellules Plateforme Transdermique Collaboration En R&D
BRIEF

published on 01/09/2026 at 00:05, 8 months 3 days ago

LIR Life Sciences Collaborates with Neuland Labs on Peptide Development

R&D Collaboration LIR Life Sciences Neuland Laboratories Cell Penetrating Peptides Transdermal Platform
PRESS RELEASE

published on 01/09/2026 at 00:00, 8 months 3 days ago

LIR Life Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform
LIR Life Sciences Corp. enters R&D Agreement with Neuland Labs for peptide formulations. Neuland Labs to provide services for preclinical evaluation and future collaboration

Lir Life Sciences Corp. Neuland Labs R&D Agreement Peptide Formulations Preclinical Evaluation

Accesswire

Published on 09/12/2026 at 02:35, 17 hours 54 minutes ago

Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 21 hours 29 minutes ago

Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 22 hours 24 minutes ago

Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 23 hours 4 minutes ago

Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 1 day 3 hours ago

Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors

View all ACCESSWIRE

EQS Group

Published on 09/12/2026 at 17:50, 2 hours 39 minutes ago

New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Published on 09/12/2026 at 07:30, 12 hours 59 minutes ago

NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 22 hours 14 minutes ago

Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 22 hours 19 minutes ago

Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 1 day ago

DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031

Les Echos

Published on 09/11/2026 at 07:00, 1 day 13 hours ago

Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 1 day 13 hours ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 1 day 13 hours ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 13 hours ago

BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 2 days ago

Availability of the 2026 Interim Financial Report

View all LES ECHOS COMFI WIRE